Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study

Beam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon enter the market. In Beam’s Phase 1/2 trial, known as ...